Tilray Medical Introduces Cannabis Edibles in Australia
Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), has launched its first medical cannabis edibles in Australia with the introduction of Good Supply Pastilles. The sugar-free and vegan-friendly pastilles are available in three varieties:
- Good Supply Pastilles THC10 (Strawberry)
- Good Supply Pastilles THC10 CBD10 (Pineapple)
- Good Supply Pastilles CBD20 (Raspberry)
The products are available in 60-pack quantities through Tilray Direct or local medical cannabis distributors. This expansion reinforces Tilray's position as a leading provider of EU-GMP certified medical cannabis, currently offering THC and CBD products across more than 20 countries and supporting medical trials globally.
Tilray Medical, una divisione di Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), ha lanciato i suoi primi prodotti commestibili a base di cannabis medica in Australia con l'introduzione di Good Supply Pastilles. Le pastiglie, senza zucchero e adatte ai vegani, sono disponibili in tre varianti:
- Good Supply Pastilles THC10 (Fragola)
- Good Supply Pastilles THC10 CBD10 (Ananas)
- Good Supply Pastilles CBD20 (Lampone)
I prodotti sono disponibili in confezioni da 60 pezzi tramite Tilray Direct o distributori locali di cannabis medica. Questa espansione rafforza la posizione di Tilray come fornitore leader di cannabis medica certificata EU-GMP, offrendo attualmente prodotti a base di THC e CBD in più di 20 paesi e supportando studi clinici a livello globale.
Tilray Medical, una división de Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), ha lanzado sus primeros comestibles de cannabis medicinal en Australia con la introducción de Good Supply Pastilles. Las pastillas, sin azúcar y aptas para veganos, están disponibles en tres variedades:
- Good Supply Pastilles THC10 (Fresa)
- Good Supply Pastilles THC10 CBD10 (Piña)
- Good Supply Pastilles CBD20 (Frambuesa)
Los productos están disponibles en paquetes de 60 unidades a través de Tilray Direct o distribuidores locales de cannabis medicinal. Esta expansión refuerza la posición de Tilray como proveedor líder de cannabis medicinal certificado EU-GMP, ofreciendo actualmente productos con THC y CBD en más de 20 países y apoyando ensayos médicos a nivel mundial.
틸레이 메디컬은 Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY)의 자회사로, Good Supply Pastilles를 통해 호주에서 첫 번째 의료용 대마초 식용 제품을 출시했습니다. 설탕이 없고 비건 친화적인 이 파스티유는 세 가지 종류로 제공됩니다:
- Good Supply Pastilles THC10 (딸기맛)
- Good Supply Pastilles THC10 CBD10 (파인애플맛)
- Good Supply Pastilles CBD20 (라즈베리맛)
제품은 Tilray Direct 또는 현지 의료용 대마초 유통업체를 통해 60개들이 패키지로 구매할 수 있습니다. 이번 확장은 EU-GMP 인증을 받은 의료용 대마초의 선도적 공급자로서 Tilray의 입지를 강화하며, 현재 20개 이상의 국가에서 THC 및 CBD 제품을 제공하고 전 세계 의료 시험을 지원하고 있습니다.
Tilray Medical, une division de Tilray Brands, Inc. (NASDAQ : TLRY ; TSX : TLRY), a lancé ses premiers produits comestibles de cannabis médical en Australie avec l'introduction des Good Supply Pastilles. Ces pastilles sans sucre et adaptées aux vegans sont disponibles en trois variétés :
- Good Supply Pastilles THC10 (Fraise)
- Good Supply Pastilles THC10 CBD10 (Ananas)
- Good Supply Pastilles CBD20 (Framboise)
Les produits sont disponibles en pack de 60 via Tilray Direct ou des distributeurs locaux de cannabis médical. Cette expansion renforce la position de Tilray en tant que fournisseur leader de cannabis médical certifié EU-GMP, proposant actuellement des produits THC et CBD dans plus de 20 pays et soutenant des essais médicaux à l’échelle mondiale.
Tilray Medical, eine Sparte von Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), hat in Australien seine ersten medizinischen Cannabis-Esswaren mit der Einführung der Good Supply Pastilles auf den Markt gebracht. Die zuckerfreien und veganfreundlichen Pastillen sind in drei Varianten erhältlich:
- Good Supply Pastilles THC10 (Erdbeere)
- Good Supply Pastilles THC10 CBD10 (Ananas)
- Good Supply Pastilles CBD20 (Himbeere)
Die Produkte sind in 60er-Packungen über Tilray Direct oder lokale medizinische Cannabisvertriebe erhältlich. Diese Erweiterung stärkt Tilrays Position als führender Anbieter von EU-GMP-zertifiziertem medizinischem Cannabis, das derzeit THC- und CBD-Produkte in mehr als 20 Ländern anbietet und weltweit medizinische Studien unterstützt.
- First-mover advantage in Australian medical cannabis edibles market
- Product line expansion into new delivery format
- Geographic market penetration strengthened in Australia
- Diversification of product portfolio with three different THC/CBD combinations
- None.
Insights
Tilray's expansion into Australian medical cannabis edibles market represents strategic product diversification, though financial impact likely modest without initial market size projections.
Tilray Medical's launch of cannabis edibles in Australia represents an important strategic expansion in the company's international product portfolio. The introduction of Good Supply Pastilles marks their first medical cannabis edibles offering in Australia, diversifying beyond traditional consumption methods into a sugar-free, vegan-friendly format that addresses specific patient preferences.
This product extension aligns with Tilray's broader international strategy as they continue building their presence in developing cannabis markets worldwide. Australia represents a growing medical cannabis market where Tilray can leverage its EU-GMP certification - a significant competitive advantage in highly regulated markets with stringent quality standards.
The three formulation varieties (THC10, THC10 CBD10, and CBD20) demonstrate Tilray's approach to meeting diverse patient needs with varied cannabinoid profiles. This formats-based expansion strategy has been successful in more mature markets, where alternative delivery methods often capture patients who avoid inhalation products.
While this launch demonstrates continued execution of Tilray's international growth strategy, investors should view it as an incremental positive rather than transformative. Without market sizing data or revenue projections, we can assume this represents a modest initial contribution to Tilray's
The introduction of pastilles to Tilray's Australian product line addresses a critical need in medical cannabis administration. Edible formats provide distinct therapeutic advantages for specific patient populations who may find traditional delivery methods challenging or inappropriate.
The three formulations offered represent thoughtful clinical consideration: THC10 (primarily psychoactive) for patients requiring pain management, appetite stimulation, or sleep support; THC10 CBD10 (balanced) for patients who benefit from THC but need CBD's moderating effects to reduce side effects; and CBD20 (non-psychoactive) for patients seeking anti-inflammatory, anxiolytic or anticonvulsant properties without impairment.
Edibles provide extended duration of effects compared to inhalation methods - typically 6-8 hours versus 2-3 hours - making them particularly valuable for chronic conditions requiring sustained symptom management. The sugar-free formulation is notably beneficial for patients with diabetes or metabolic concerns who must monitor sugar intake carefully.
For patients with respiratory conditions, compromised immune systems, or those who simply prefer not to inhale substances, edibles represent a necessary alternative. The 60-count packaging suggests Tilray is positioning these for regular, ongoing treatment rather than acute symptom management.
From a medical perspective, having diverse administration options improves treatment adherence and patient satisfaction. This expansion demonstrates Tilray's commitment to patient-centered product development, addressing the reality that medical efficacy isn't solely about cannabinoid content but also about practical administration considerations.
Tilray Medical Expands Offerings with Good Supply Brand Medical Cannabis Pastilles for Australian Patients
SYDNEY, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.
Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, stated, "Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences. The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone for Tilray Medical. We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide."
Good Supply Pastilles are available in the following options:
- Good Supply Pastilles THC10 (Strawberry)
- Good Supply Pastilles THC10 CBD10 (Pineapple)
- Good Supply Pastilles CBD20 (Raspberry)
Medical cannabis patients are now able to purchase the Good Supply Pastilles in packs of 60 from Tilray Direct or their local medical cannabis distributors.
Tilray continues to be a leading provider of EU-GMP certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers globally. Today, Tilray offers a comprehensive portfolio of THC and CBD products in over 20 countries, supporting medical trials worldwide to study the efficacy of medical cannabis for various conditions.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is a leading supplier of medical cannabis with a portfolio of brands and products designed to meet the needs of our patients worldwide.
For further information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media: news@tilray.com
Investor Relations: investors@tilray.com
FAQ
What new medical cannabis products did Tilray (TLRY) launch in Australia in April 2025?
How can patients in Australia access Tilray's new Good Supply Pastilles?
What are the key features of Tilray's Good Supply Pastilles for medical cannabis patients?
How many countries does Tilray (TLRY) currently distribute medical cannabis products to?
